clinical trials glp-1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy The transformative breakthroughs in GLP-1

The key milestones include: exenatide approval (2005), liraglutide approval (2010), semaglutide injection approval (2017), oral semaglutide with SNAC approval (2019), orforglipron cryo-EM structure published (2020), orforglipron Phase 2 results in NEJM (2023), orforglipron Phase 3 ATTAIN-1 results in NEJM (2025), and FDA regulatory submission (2025)

While usually mild to moderate, severe or persistent abdominal pain requires evaluation to exclude serious complications

No Wheat, Gluten, Soybeans, Dairy, Egg, Fish/Shellfish, Peanuts/Tree Nuts or Sesame

They are appropriate for demanding applications because of their capacity to deliver high discharge rates

[2] Treatment typically starts with 3 mg once daily for 30 days, then increases to 7 mg daily, with a possible further increase to 14 mg if needed for glycaemic control